Sign In
Buy LLY
$1,185.71
-7.09 (-0.594%)
At Close: Aug 07, 2026
Mounjaro becomes second weight loss drug to receive NICE green light
03:35am, Wednesday, 05'th Jun 2024
The National Institute for Health and Care Excellence (NICE) in England has approved a second drug to combat obesity, offering a more effective alternative to semaglutide. The newly approved drug, tir
Eli Lilly and Company (LLY) Lilly Oncology ASCO Investor Event (Transcript)
01:33pm, Tuesday, 04'th Jun 2024
Eli Lilly and Company (NYSE:LLY ) Lilly Oncology ASCO Investor Event June 2, 2024 8:30 PM ET Company Participants Jake Van Naarden - Executive VP & President of Loxo Lillian Smyth - Senior Vice Presid
Britain considers offering Lilly weight-loss drug on better terms than Wegovy
12:59pm, Tuesday, 04'th Jun 2024
Britain's medical costs regulator on Tuesday recommended Eli Lilly's weight-loss drug Mounjaro for some patients with obesity and suggested not placing a time limit on the medicine's use as it had for
Melissa Seymour to join Lilly as executive vice president of Global Quality
09:00am, Tuesday, 04'th Jun 2024
INDIANAPOLIS , June 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Melissa Seymour will join the company as executive vice president of Global Quality and member of the
LLY Stock Today: How To Trade An Unbalanced Iron Condor That May Put $285 In Your Pocket
02:54pm, Monday, 03'rd Jun 2024
The profit zone ranges between 757.15 and 912.85.
Beyond The Nvidia Juggernaut: 2 Chip Giants, 2 Drugmakers In Spotlight
02:14pm, Monday, 03'rd Jun 2024
As Nvidia stock takes aim at another record high and market-cap dominance, AMD and TSM set up alongside two top drugmakers.
Bullish on LLY, GOOGL, META
01:03pm, Monday, 03'rd Jun 2024
Eli Lilly (LLY), Alphabet (GOOGL), and Meta Platforms (META) are today's big three stocks. Joel Hawthorne and Ben Lichtenstein discuss the technical trends, as well as how to trade these names.
Watch Out Wegovy: Here Comes Another Promising Anti-Obesity Candidate
09:45am, Monday, 03'rd Jun 2024
One of Eli Lilly's anti-obesity candidates reported positive data in a phase 3 study. The results highlight the strong breadth of Lilly's portfolio in this promising area.
Earn An 'Embarrassing' Amount Of Cash Flow From These Contrarian Picks
08:10am, Monday, 03'rd Jun 2024
Amazon CEO Andy Jassy highlights key traits for success in a career professional, including working hard, being can-do, and following through on commitments. There are different paths to success, and
Four Stocks Making New Highs Despite Market Weakness
07:30am, Monday, 03'rd Jun 2024
Despite the market's dramatic sell-off on Friday, some stocks showed impressive strength by making new 52-week highs. While big tech led the market decline, these four stocks, Birkenstock, NetApp, Eli
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
09:30am, Sunday, 02'nd Jun 2024
Eli Lilly and Novo Nordisk are leaders in fast-growing therapeutic areas. Both companies have excellent track records of innovations and solid results.
Eli Lilly's Growth And Challenges: A Cautious Buy
05:11pm, Saturday, 01'st Jun 2024
Eli Lilly announced impressive Q1 2024 financial results, with revenue surging by 26% YoY and exceeding expectations for earnings per share. The company raised its full-year 2024 revenue guidance and
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
10:25am, Saturday, 01'st Jun 2024
Eli Lilly and Novo Nordisk have generated incredible returns for investors in the past few years. The surging popularity of their weight loss treatments has produced a lot of bullishness.
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
08:00am, Saturday, 01'st Jun 2024
Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
08:00am, Saturday, 01'st Jun 2024
Data demonstrated promising monotherapy activity with olomorasib across a range of KRAS G12C-mutant solid tumors, including non-small cell lung cancer, and a tolerability profile in combination with p
